DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

11 Aug 2022

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

The Uganda DolPHIN-2 team had a successful second day at #JASHC2022 promoting the effectiveness and acceptability of dolutegravir in late #pregnancy #HIV #clinicalresearch https://t.co/S0aVJXqUtH

3 days 13 hours ago

The DolPHIN2 team from Uganda were at #JASHC2022 presenting results from our clinical trial and qualitative research that support the use of dolutegravir in #pregnancy #HIV #clinicaltrials https://t.co/eexJVR4Cmb

1 week 12 hours ago

RT @LivUni: https://t.co/xG5H2J7uMI

2 weeks 6 days ago

RT @At_The_EQUATOR: #WorldBreastfeedingWeek2022 Breast milk is the best choice for the baby and the mother. Fathers have to step up and support their #breastfeeding partners. #BreastfeedingWeek #WBW2022 #BreastMilkDonation #educateandsupport @cgbanda @paulkgonza @livuninews @wellcometrust @okoboi25 https://t.co/dzIocX3nZe

1 month 4 weeks ago

RT @drlaurajwaters: #AIDS2022 @CatrionaWaitt summarising optimal DTG use in women - they key is COMMUNICATION & ONGOING DIALOGUE. Hell yes to that! This is a great slide https://t.co/zyWiuM1pBY

2 months 4 hours ago

RT @CatrionaWaitt: @AIDS_conference #AIDS2022 @agenceANRS @UNITAID @UoLDolphin2 @modernart4sa exhibition in Global Village. Bringing art and film to creatively engage on many HIV related topics. The leaflets are great - come and visit! https://t.co/2PS2QWa8jP

2 months 1 day ago

RT @CatrionaWaitt: I am looking forward to attending this in person. Colleagues on Twitter - online option here @JacquelineKyey1 @SemakulaRitah @JoviaMirembe6 @SeniorCymo @fwojara @UoLDolphin2 @MagoolaJohnson @IDIMakerere https://t.co/IUNW62pLlI

2 months 1 day ago

Read about the Trio pooled data analysis that DolPHIN2 contributed to @LivUniISMIB @LSTMnews @IDIMakerere @EpiBiostats_UCT @radboudumc https://t.co/FYHQzFpDnV

2 months 1 day ago

RT @TRIO_ARToptim: Thank you very much to joined @TRIO_ARToptim during the satellite symposium @AIDS_conference @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi https://t.co/w4IHcCPLHU

2 months 1 day ago

RT @TRIO_ARToptim: TRIO SYMPOSIUM Move to session 2: Community engagement @TRIO_ARToptim @AIDS_conference @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi #AIDS2022 https://t.co/c1qovLraGB

2 months 1 day ago

RT @TRIO_ARToptim: LIVE ! TRIO Symposium Treatment Optimisation: lessons from TRIO- ADVANCE, DOLPHIN2 AND NAMSAL- ANRS-12313 trial funded by UNITAID @TRIO_ARToptim @AIDS_conference @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi #AIDS2022 https://t.co/AIriEyjgV2

2 months 1 day ago

RT @CatrionaWaitt: @TRIO_ARToptim @UNITAID @AIDS_conference symposium is underway! Room 517b/ Channel 4 - join us! https://t.co/ShNvh0G8OB

2 months 1 day ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

Empower, Engage, Educate - Breastfeeding

Empower, Engage, Educate - Delivery

Empower, Engage, Educate - Male Involvement

Empower, Engage, Educate - Mumbwa

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us